Alkermes plc (8AK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alkermes plc (8AK) has a cash flow conversion efficiency ratio of -0.095x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-165.74 Million ≈ $-193.77 Million USD) by net assets (€1.75 Billion ≈ $2.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 8AK company net worth for the company's overall valuation and market capitalisation.
Alkermes plc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Alkermes plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alkermes plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes plc ranked by their cash flow conversion efficiency. Explore 8AK cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unicaja Banco SA
MC:UNI
|
0.006x |
|
Sailun Jinyu Group Co Ltd
SHG:601058
|
0.071x |
|
PACS Group, Inc.
NYSE:PACS
|
0.333x |
|
Terex Corporation
NYSE:TEX
|
0.026x |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
1.029x |
|
Artemis Gold Inc
V:ARTG
|
0.196x |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
0.038x |
|
Lamb Weston Holdings Inc
NYSE:LW
|
0.190x |
Annual Cash Flow Conversion Efficiency for Alkermes plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes plc from 2013 to 2025. View Alkermes plc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.82 Billion ≈ $2.13 Billion |
€520.75 Million ≈ $608.82 Million |
0.286x | -4.51% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
€439.12 Million ≈ $513.38 Million |
0.300x | -10.18% |
| 2023-12-31 | €1.20 Billion ≈ $1.41 Billion |
€401.35 Million ≈ $469.22 Million |
0.334x | +1555.17% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
€21.04 Million ≈ $24.60 Million |
0.020x | -77.95% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
€101.72 Million ≈ $118.92 Million |
0.091x | +7.86% |
| 2018-12-31 | €1.17 Billion ≈ $1.37 Billion |
€99.28 Million ≈ $116.07 Million |
0.085x | +431.28% |
| 2017-12-31 | €1.20 Billion ≈ $1.41 Billion |
€19.19 Million ≈ $22.44 Million |
0.016x | +130.24% |
| 2016-12-31 | €1.21 Billion ≈ $1.41 Billion |
€-63.80 Million ≈ $-74.59 Million |
-0.053x | -71.78% |
| 2015-12-31 | €1.31 Billion ≈ $1.54 Billion |
€-40.36 Million ≈ $-47.19 Million |
-0.031x | -485.09% |
| 2014-12-31 | €1.40 Billion ≈ $1.63 Billion |
€11.14 Million ≈ $13.02 Million |
0.008x | -94.24% |
| 2013-12-31 | €1.07 Billion ≈ $1.25 Billion |
€147.53 Million ≈ $172.47 Million |
0.138x | -- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more